Novo Nordisk will take Dicerna's technology to the next level, says EVP

Dicerna's technology platform will presumably result in several new drug candidates within Novo Nordisk's disease areas, says Executive Vice President & Chief Scientific Officer at Novo Nordisk Marcus Schindler.

Photo: Novo Nordisk / PR

Novo Nordisk's acquisition of the US-based biotech company for USD 3.3bn follows a two-year-long successful collaboration, and signals that more drug candidates from Dicerna's technology platform targeting Novo's focus areas could be on their way in the future, says Marcus Schindler, executive vice president and chief scientific officer at Novo Nordisk, to MarketWire.

The biotech company, which is based in Lexington, has specialized within RNA interference (RNAi), a technology where specific genes are suppressed before they can produce proteins that contribute to disease progression.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs